Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe

AIM: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed‐dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α‐blocker), on health‐related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rees, Jonathan, Foley, Steve, Huang, Moses, Rosa Arias, José, Skoumal, René, Walters, Carien, Yavuz, Yalcin, De Wachter, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916269/
https://www.ncbi.nlm.nih.gov/pubmed/30801782
http://dx.doi.org/10.1002/nau.23944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916269/
https://www.ncbi.nlm.nih.gov/pubmed/30801782
http://dx.doi.org/10.1002/nau.23944

Ejemplares similares